Gene therapy trial targets rare brain disease
NCT ID NCT04680065
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a gene therapy called AAV2-GDNF for multiple system atrophy (MSA), a rare and serious brain disorder. Nine adults with MSA will receive either the gene therapy or a sham surgery. The main goal is to check safety, but researchers will also look for any signs of symptom improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AAV2-GDNF gene therapy
What this could lead to
If safe and effective, this could point toward a treatment that slows or improves symptoms of multiple system atrophy.
What could go wrong
This is a very early Phase 1 trial with only 9 people, focused on safety. It may not show any benefit, and gene therapy carries risks like inflammation or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, 33486, United States
-
Quest Research Institute
Farmington Hills, Michigan, 48334, United States
-
The Ohio State University Medical Center
Columbus, Ohio, 43210, United States
-
University of California Irvine
Irvine, California, 92697, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States